Information on the efficacy and safety of molnupiravir in daily clinical practice is very scarce.
We aimed to describe the clinical characteristics and outcomes of fully vaccinated patients …

Vaccines remain the cornerstone of medical prevention and are highly effective in reducing
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …

Background Molnupiravir is an orally administered antiviral authorized for COVID-19
treatment in adults at high risk of progression to severe disease. Here, we report secondary …

Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …

Summary Introduction Continued SARS-CoV-2 infection among immunocompromised
individuals is likely to play a role in generating genomic diversity and the emergence of …

Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …

At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …

Information Classification: General impact on the morbidity and mortality of patients
worldwide. In an effort to address this ongoing public health crisis, researchers and …

It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been
elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 …